# A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)

> **NCT02607202** · PHASE2 · COMPLETED · sponsor: **Fondazione del Piemonte per l'Oncologia** · enrollment: 57 (actual)

## Conditions studied

- Unknown Primary Tumors

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02607202
- **Lead sponsor:** Fondazione del Piemonte per l'Oncologia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2021-05-04
- **Final completion:** 2022-01-31
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02607202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02607202, "A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02607202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*